1 reports of this reaction
5.3% of all LIQUID BANDAGE reports
#10 most reported adverse reaction
PURPURA is the #10 most commonly reported adverse reaction for LIQUID BANDAGE, manufactured by AmerisourceBergen Drug Corporation. There are 1 FDA adverse event reports linking LIQUID BANDAGE to PURPURA. This represents approximately 5.3% of all 19 adverse event reports for this drug.
Patients taking LIQUID BANDAGE who experience purpura should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PURPURA is moderately reported among LIQUID BANDAGE users, representing a notable but not dominant share of adverse events.
In addition to purpura, the following adverse reactions have been reported for LIQUID BANDAGE:
PURPURA has been reported as an adverse event in 1 FDA reports for LIQUID BANDAGE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PURPURA accounts for approximately 5.3% of all adverse event reports for LIQUID BANDAGE, making it a notable side effect.
If you experience purpura while taking LIQUID BANDAGE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.